ADCT
ADC Therapeutics SA
1.30$
-1.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
ADC Therapeutics SA (ADCT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -12 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -31 | -31 | -30 | -30 | -28 | -28 | -32 | -34 | -32 | -41 | -44 | -52 | -55 | -58 | -59 | -62 | -34 | -53 | 2.2 | -54 | -15 | -35 | -37 | -33 | -44 | -33 | -25 | -22 | -56 | -24 | -30 | -31 | -30 | -12 | -102 | |
| 0.1 | 0.1 | 0.1 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.5 | 0.8 | 0.6 | 0.6 | 0.7 | 0.8 | 0.6 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.9 | 1.5 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 1.2 | 0.1 | 0.1 | 0.1 | 1.1 | 1.4 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.8 | 3.8 | 13 | 11 | 15 | 14 | 18 | 15 | 13 | 13 | 14 | 15 | 7.5 | 8.1 | 1.1 | 2.1 | 2.2 | 0.2 | 2.0 | 2.8 | 1.6 | 2.4 | 1.8 | 2.0 | 6.1 | 2.4 | 4.6 | 15 | |
| 0.2 | 0.2 | – | – | 0.2 | 0.2 | 0.5 | 0.3 | 46 | 46 | -22 | -6.3 | -5.9 | 12 | 26 | -18 | -16 | -5.7 | 57 | 15 | 13 | 13 | 13 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.0 | 1.0 | 0.2 | 0.9 | 0.4 | 0.4 | -1.8 | 1.0 | 7.0 | -0.5 | -2.2 | 9.9 | 1.8 | 1.5 | -14 | -9.6 | -1.6 | 16 | -4.7 | -58 | 33 | 5.0 | -0.5 | 10 | -9.9 | -4.8 | 8.5 | 10 | -30 | 15 | 0.4 | -12 | -5.0 | 11 | -5.5 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.2 | 0.5 | 0.1 | 1.4 | 0.8 | 0.7 | 0.9 | 2.3 | 0.5 | 1.1 | 0.8 | 0.3 | 0.2 | 1.0 | 1.2 | 0.7 | 0.3 | 0.5 | 0.0 | 0.2 | 0.1 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.3 | -0.3 | -1.0 | -1.0 | -1.0 | -1.0 | 0.0 | -0.3 | -0.5 | -0.1 | -1.4 | -0.8 | -0.7 | -2.8 | -2.3 | -0.8 | -1.4 | -0.7 | -0.3 | 1.7 | -1.0 | -1.2 | -0.7 | -0.5 | -0.5 | 0.0 | -0.2 | -0.1 | -0.3 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.7 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0 | – | 0.0 | – | 101 | -0.1 | 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | – | -0.2 | – | – | – | 0.0 | – | – | – | -1.2 | 0.0 | -0.3 | – | – | 0.0 | 0.0 | – | |
| -0.3 | -0.3 | – | – | -0.3 | -0.3 | -0.3 | -0.2 | 31 | 31 | -0.3 | -0.2 | -0.3 | 49 | -0.2 | -0.2 | -0.3 | -0.3 | -3.8 | -2.2 | -0.4 | -0.4 | -0.4 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | 50 | 50 | -0.3 | -0.1 | -0.3 | 307 | 191 | -2.9 | -0.3 | 49 | 219 | -1.2 | -0.3 | -0.3 | 2.4 | -2.7 | 0.4 | 73 | 0.3 | 1.0 | 0.4 | 99 | -0.9 | -1.1 | 0.3 | 94 | -0.2 | 58 | -0.6 | -0.1 | 57 | |
| -31 | -31 | -31 | -31 | 22 | 22 | -33 | -34 | -33 | 266 | 146 | -55 | -56 | -11 | 158 | -64 | -36 | -54 | 4.1 | -54 | -16 | 37 | -37 | -32 | -44 | 66 | -26 | -23 | -56 | 70 | -30 | 27 | -30 | -12 | -45 | |
| -31 | -31 | -30 | -30 | -28 | -28 | -32 | -34 | -33 | -41 | -46 | -52 | -56 | -59 | -61 | -62 | -35 | -54 | 1.9 | -54 | -16 | -36 | -37 | -33 | -45 | -33 | -25 | -22 | -57 | -24 | -30 | -31 | -30 | -12 | -102 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.